Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3024235 | 0.98 | IDO1 (0.42) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL17439882 | 0.82 | PDE2A (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| Hydrochloric Acid SCHEMBL28666635 | 0.80 | PDE2A (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL20238027 | 0.78 | IDO1 (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL26931399 | 0.78 | IDO1 (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL20238028 | 0.78 | IDO1 (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL29669053 | 0.78 | IDO1 (0.41) | PDE2AIDO1TDO2HSD11B1CES2 | |
| SCHEMBL23139487 | 0.78 | PDE2A (0.48) | PDE2AIDO1TDO2CES2CES1 | |
| SCHEMBL29394861 | 0.78 | PDE2A (0.48) | PDE2AIDO1TDO2CES2CES1 | |
| SCHEMBL29621462 | 0.78 | PDE2A (0.48) | PDE2AIDO1TDO2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| WO-2006067414-A2 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216837-A1 | GLYCINE TRANSPORT INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | PDE2A 1525/4885IDO1 516/4885TDO2 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.